Where blood levels are genuinely low, replacement repairs the bone disease that defined the deficiency. Where levels are already adequate, large trials show no fewer fractures, less cancer, or longer life. Steady modest daily amounts are well tolerated; large infrequent doses have increased falls and broken bones, and pushing levels higher raises calcium without further gain. (Full Review)

Protocol

Standard maintenance dose

1000–2000 IU D3 daily

Adjusted upward for higher body weight, darker skin, and limited sun exposure

Correcting documented deficiency

5000 IU daily for 8–12 weeks

Or 50,000 IU weekly for 6–8 weeks, then retesting and a lower maintenance dose

Form

Vitamin D3 (cholecalciferol)

Raises and maintains 25(OH)D more effectively than vitamin D2 (ergocalciferol)

Time to effect

Deficiency symptoms

3–6 months

Osteomalacic bone pain and biochemical abnormalities resolve on replacement

Non-skeletal endpoints

3–5 years

Timeframe required in trials

Blood levels

8–12 weeks

25(OH)D plateaus after any dose change

Benefits

High: Correction of deficiency-related bone disease; prevention of type 2 diabetes in prediabetes

Medium: Lower cancer mortality; reduced incidence of autoimmune disease; reduced risk of acute respiratory infection

Low: Fracture risk reduction with combined calcium; improved muscle strength and fall risk in deficiency; slowed markers of biological aging; reduced depressive symptoms

Speculative: Lower dementia and cognitive decline risk; reduced risk of multiple sclerosis onset

Contraindications

Active granulomatous disease (sarcoidosis, tuberculosis) or calcitriol-producing lymphoma

Primary hyperparathyroidism with serum calcium above 10.5 mg/dL

Any pre-existing hypercalcemia, including hypercalcemia of malignancy

Inherited CYP24A1 deficiency or Williams syndrome

Chronic kidney disease stage 4–5 (eGFR below 30 mL/min/1.73 m²) without nephrology supervision

Recurrent calcium-oxalate nephrolithiasis with documented high urinary calcium, unless urinary calcium is monitored

Key Interactions

Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide)

Digoxin and other cardiac glycosides

Anticonvulsants (phenytoin, phenobarbital, carbamazepine)

Rifampin and other strong enzyme inducers

Glucocorticoids (prednisone, dexamethasone)

Ketoconazole and other azole antifungals

Statins (atorvastatin, simvastatin)

Over-the-counter fat-absorption inhibitors and adsorbents (orlistat, mineral oil, activated charcoal)

Over-the-counter bile acid sequestrants (cholestyramine, colesevelam)

Over-the-counter antacids and calcium carbonate

Calcium supplements

Vitamin A (retinol) at high dose

Vitamin K2 (menaquinone-4 and menaquinone-7)

Magnesium

Calcitriol and vitamin D analogues (paricalcitol, alfacalcidol, doxercalciferol)

Ultraviolet exposure and tanning beds

Risk & Side Effects

High: Hypercalcemia and hypercalciuria; increased falls and fractures with high-dose intermittent dosing

Medium: Dose-dependent reduction in bone mineral density; kidney stones with calcium co-supplementation

Low: Gastrointestinal intolerance at high intake; overdose from mislabelled or compounded products

Speculative: Sleep disruption with evening or high doses; vascular calcification with inadequate vitamin K status

Monitoring

Marker	Target	Why
25-hydroxyvitamin D	30–50 ng/mL	Primary status marker and the variable every dose decision turns on
Serum calcium (albumin-corrected)	8.8–10.0 mg/dL	Detects the principal harm before symptoms appear
Parathyroid hormone (PTH)	15–45 pg/mL	Confirms whether a low 25(OH)D is biologically meaningful; falls as deficiency corrects
24-hour urinary calcium	Under 250 mg (women) / 300 mg (men)	Identifies hypercalciuria, the step that converts vitamin D into stone risk
Serum phosphate	2.5–4.0 mg/dL	Rises with vitamin D-driven absorption; low values suggest ongoing deficiency
RBC magnesium	4.2–6.8 mg/dL	Cofactor for activation and inactivation; low status blunts the response to any dose
Estimated glomerular filtration rate (eGFR)	Above 60 mL/min/1.73 m²	Kidney function governs activation and sets the ceiling on safe calcium loading
Alkaline phosphatase	40–100 U/L	Elevated in osteomalacia; normalizes as bone mineralization is restored

Cadence: 25(OH)D and albumin-corrected serum calcium at 12 weeks after starting or any dose change, then annually on a stable dose. Twice-yearly above 4000 IU daily, at latitudes with strong seasonal swings, or alongside thiazide diuretics.

Qualitative Assessment

Proximal muscle strength — ease of rising from a chair or climbing stairs without using hands
Diffuse bone or muscle aching, particularly in ribs, hips, and shins
Frequency and duration of upper respiratory infections across a winter season
Energy levels and seasonal mood variation through the low-sunlight months
Balance confidence and any change in near-fall frequency, especially after a dose increase
New nausea, constipation, excessive thirst, or frequent urination

Vitamin D for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment